文献速递脑血管病神经重症与神经感染

磺脲类药物可降低糖尿病患者原发性脑出血及血肿周围水肿体积

Reduced Intracerebral Hemorrhage and Perihematomal Edema Volumes in Diabetics on Sulfonylureas.
PubMed 文献 · Stroke · 2019-01-01

本研究回顾性分析2006至2016年两家三级学术中心收治的糖尿病患者原发性脑出血病例,比较21例入院时使用磺脲类药物者与42例匹配对照者的影像与结局。磺脲脲组入院脑出血体积、血肿周围水肿体积及水肿/血肿表面积比均显著更低,且出院去向更优。

要点

  • 糖尿病合并原发性脑出血患者中,磺脲类药物使用与更小的入院血肿体积相关。
  • 磺脲类药物使用与更低的血肿周围水肿体积及相对水肿程度相关。
  • 磺脲类药物使用与更好的出院去向相关,需进一步研究验证。

核心结论

  • 在糖尿病合并原发性脑出血患者中,磺脲类药物使用预测更低的脑出血体积、血肿周围水肿体积、相对水肿程度及更好的出院去向。

研究设计与样本

  • 回顾性病历回顾研究,纳入2006至2016年两家三级学术中心收治的糖尿病合并原发性脑出血患者。
  • 共筛选317例患者,最终纳入21例磺脲脲类药物使用病例和42例匹配对照。
  • 对照按入院日期、年龄、血肿位置(深部或脑叶)、抗血小板或抗凝药物使用进行2:1匹配。
  • 通过入院CT感兴趣区分析测量脑出血体积和血肿周围水肿体积,并计算水肿/血肿表面积比。

主要发现

  • 磺脲脲组入院脑出血体积中位数4 mL(IQR 2-30),对照组中位数25 mL(IQR 6-60),P=0.011。
  • 磺脲脲组血肿周围水肿体积中位数4 mL(IQR 0.9-24),对照组中位数17 mL(IQR 6-37),P=0.0095。
  • 磺脲脲组水肿/血肿表面积比中位数0.28(IQR 0.1-0.4),对照组中位数0.43(IQR 0.3-0.6),P=0.013。
  • 磺脲脲类药物使用与更好的出院去向相关(P=0.0062)。

临床怎么用

  • 对于糖尿病合并原发性脑出血患者,入院时使用磺脲脲类药物可能与更小的血肿和水肿体积及更好结局相关。
  • 鉴于原发性脑出血治疗选择有限,磺脲脲类药物的潜在获益值得进一步前瞻性研究验证。

局限性

  • 本研究为回顾性病历回顾,样本量较小(21例病例和42例对照),可能存在选择偏倚和未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Sulfonylurea medications have been linked to reduced brain edema and improved outcome following ischemic stroke, but their effects on primary intracerebral hemorrhage (pICH) have not been thoroughly explored. Increasing ICH volume and perihematomal edema (PHE) volume are predictors of poor outcome in pICH. We investigated whether preexisting sulfonylurea use influenced ICH volume, PHE volume, and discharge disposition in patients with type 2 diabetes mellitus presenting with pICH. Methods- We performed a retrospective chart review of all diabetic patients presenting with pICH to 2 tertiary academic centers from 2006 to 2016. All patients with diabetes mellitus, pICH, admission computed tomography scan, and sulfonylurea use on admission were included in our study. For each case, 2-matched controls (admission date, age, hematoma location [deep versus lobar], use of antiplatelet, or anticoagulant) with diabetes mellitus and pICH were consecutively selected. ICH and PHE volumes were measured via region of interest analysis on admission computed tomography. To mitigate the influence of ICH volume on PHE, the PHE/ICH surface area ratio was calculated. Hospital discharge disposition was determined via chart abstraction. We used the Wilcoxon rank-sum test and Fisher exact test to compare cases and controls. Results- Of 317 patients screened, 21 sulfonylurea cases and 42-matched controls met criteria for study inclusion. Sulfonylurea cases had significantly lower admission ICH volumes (median, 4 mL; interquartile range [IQR], 2-30 versus median, 25 mL; IQR, 6-60; P=0.011), PHE volumes (median, 4 mL; IQR, 0.9-24 versus median, 17; IQR, 6-37; P=0.0095), and PHE/ICH surface area ratios (median, 0.28; IQR, 0.1-0.4 versus median, 0.43; IQR, 0.3-0.6; P=0.013) as compared with controls. Sulfonylureas were associated with improved discharge disposition ( P=0.0062). Conclusions- In patients with diabetes mellitus and pICH, sulfonylurea use predicted lower ICH and PHE volumes, lower relative PHE, and improved discharge disposition. Given the paucity of treatment options for pICH, further study of sulfonylureas is warranted.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Irvine H, Male S, Robertson J, et al. Reduced Intracerebral Hemorrhage and Perihematomal Edema Volumes in Diabetics on Sulfonylureas. Stroke. 2019. PMID: 30879436. doi:10.1161/STROKEAHA.118.022301

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。